Tanvex BioPharma, Inc. (TPE:6541)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
31.80
+0.20 (0.63%)
Sep 8, 2026, 1:30 PM CST

Tanvex BioPharma Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-1,465-1,500-1,382-2,137-1,641-1,543
Depreciation & Amortization
301.92320.63287.56323.59280.01241.43
Other Amortization
46.2546.11.481.241.552.15
Loss (Gain) From Sale of Assets
40.2946.91-0.082.877.210.94
Asset Writedown & Restructuring Costs
-49.19-8.67--
Stock-Based Compensation
8.979.07-2.16326.6167.5552.95
Provision & Write-off of Bad Debts
13.556.47----
Other Operating Activities
0.48-3.1517.88-1.23--90.2
Change in Accounts Receivable
-103.4211.259.33-9.062.19-2.52
Change in Inventory
-27.12-157.92-109.5562.56-80.51-40.25
Change in Accounts Payable
1.9599.59-33.41-15.59-66.97
Change in Unearned Revenue
185.89-68.36-0.56-10.9328.07-
Change in Other Net Operating Assets
61.53-65.0727.05-35.9816.8258.67
Operating Cash Flow
-934.97-1,005-1,151-1,435-1,334-1,387
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-811.47-668.26-105.91-71.02-93.5-29.82
Sale of Property, Plant & Equipment
10.8312.910.146.331.826.7
Sale (Purchase) of Intangibles
-2.48-1.94-4.86-0.32-2.58-0.52
Other Investing Activities
1,023959.11.38-18.57-3.09-1.04
Investing Cash Flow
-784.34301.8-109.25-83.57-97.35-24.68

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-30377.65---
Total Debt Issued
717.7530377.65---
Short-Term Debt Repaid
---377.65---
Long-Term Debt Repaid
--156.67-184.58-127.67-130.53-93.11
Lease Payments
-177.09-156.67-184.58-127.67-130.53-93.11
Total Debt Repaid
-282.09-156.67-562.23-127.67-130.53-93.11
Net Debt Issued (Repaid)
435.66-126.67-184.58-127.67-130.53-93.11
Issuance of Common Stock
1,2531,2641,4401,2077.241,690
Other Financing Activities
1.720.22----
Financing Cash Flow
1,6901,1381,2551,080-123.291,597

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
50.4167.640.9833.91117.75-31.25
Net Cash Flow
21.59501.75-3.79-405.48-1,437154.37

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-1,746-1,674-1,257-1,506-1,427-1,417
Free Cash Flow Growth
------
Free Cash Flow Margin
-265.59%-417.41%-3623.36%-2452.94%-6370.97%-26208.75%
Free Cash Flow Per Share
-6.66-6.83-8.09-11.69-12.14-13.05
Levered Free Cash Flow
-1,266-1,111-792.54-713.06-844.23-819.13
Unlevered Free Cash Flow
-1,235-1,082-759.2-677.19-810.03-790.24
Free Cash Flow After Leases
-1,924-1,830-1,441-1,634-1,558-1,510

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
50.9547.2353.3457.3854.7245.81
Cash Income Tax Paid
0.20.831.020.880.020.02
Change in Working Capital
118.8519.49-73.7339.99-49.03-51.08